Centrum MOVEMENT & MOBILITY

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

glucosamine sulfate sodium chloride, Quantity: 942.02 mg (Equivalent: glucosamine sulfate, Qty 750 mg); bovine sodium chondroitin sulfate, Quantity: 553.39 mg (Equivalent: chondroitin sulfate, Qty 400 mg); manganese gluconate, Quantity: 7.09 mg (Equivalent: manganese, Qty 0.875 mg); copper gluconate, Quantity: 1.79 mg (Equivalent: copper, Qty 0.25 mg)

Disponibbli minn:

Haleon Australia Pty Ltd

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: crospovidone; magnesium stearate; Carnauba Wax; povidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin

Rotta amministrattiva:

Oral

Indikazzjonijiet terapewtiċi:

Maintain/support collagen formation ; Maintain/support bone health ; Decrease/reduce/relieve mild joint aches and pains ; Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; Helps maintain/supports healthy joint cartilage growth/development/production ; Maintain/support joint health ; Maintain/support joint mobility/flexibility ; Decrease/reduce/relieve mild joint pain/soreness

Sommarju tal-prodott:

Visual Identification: ;

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2020-11-05